-
Join 92 other subscribers
-
Recent Posts
Top Rated
Most Popular:
Blogroll
Conferences
Intellectual Property
Journals
MedChem Resources
News
Organic Chemistry Resources
- Abbott
- adverse events
- allosteric
- allosteric inhibitor
- amine basicity
- Analgesic
- animal PK
- anti-viral
- AstraZeneca
- Aurora
- beta-secretase
- bioactivation
- BIRB-796
- Boehringer Ingelheim
- cancer
- cardiotoxicity
- cellular potency
- CGRP
- chloro
- CNS penetration
- computational method
- crystal packing
- CYP450
- Deuterium
- Doramapimod
- FAAH
- Fatty acid amide hydrolase
- fluorine
- free drug
- functional antagonist
- Gly-T1
- gpcr
- hepatotoxicity
- hERG
- immunosuppressant
- isostere
- kinase
- kinetic isotope effect
- Lexicon Pharmaceuticals
- LipE
- Merck
- metabolism
- mTOR
- nitrile
- Novartis
- osteoarthritis
- P-gp
- p38
- Pain
- PF-04457845
- PF-3845
- Pfizer
- Phase I
- Phase II
- Phase III
- POC
- PPB
- protein binding
- PSA
- reactive metabolite
- review
- RG1678
- rheumatoid arthritis
- Roche
- S1P1
- S1PL
- Schizophrenia
- solubility
- Structural alert
- Structure Based Design
- switch pocket
- synthesis
- toxicity
- Transporters
- X-ray data
Categories
Tag Archives: PF-04457845
Discovery of PF-04457845 (FAAH Inhibitor)
In this latest publication from the Pfizer labs, the authors describe their continuing efforts to identify urea-based, irreversible inhibitors of fatty acid amide hydrolase (FAAH). Inhibition of FAAH and the concomitant elevation of endogenous levels of fatty acid amides has … Continue reading
Posted in Clinical Candidates, Enzyme Inhibitors
Tagged Analgesic, CYP450, FAAH, Fatty acid amide hydrolase, osteoarthritis, Pain, PF-04457845, PF-3845, Pfizer, Phase II, POC, PSA
Leave a comment